Published in J Virol on March 01, 1994
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev (2000) 3.70
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol (2000) 3.26
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A (1995) 3.20
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest (1995) 2.66
Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46
Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol (1999) 2.37
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol (2004) 1.98
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol (1999) 1.93
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol (1999) 1.42
Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol (1998) 1.41
Hepatitis C: progress and problems. Clin Microbiol Rev (1994) 1.37
Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol (1998) 1.31
Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol (2009) 1.31
Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol (1999) 1.26
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol (2004) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
The evolutionary epidemiology of vaccination. J R Soc Interface (2007) 1.19
Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol (2000) 1.18
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol (2000) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol (1998) 1.13
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol (2000) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol (2012) 1.12
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3. J Virol (2000) 1.10
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol (1998) 1.09
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol (2000) 1.00
Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol (2014) 0.99
Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus. J Virol (2000) 0.99
Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol (2005) 0.99
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99
The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage. J Clin Immunol (1997) 0.96
Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol (2000) 0.96
Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96
Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol (2001) 0.94
Hepatitis C virus infection of human hepatoma cell line 7721 in vitro. World J Gastroenterol (2001) 0.94
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology (2007) 0.93
Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol (2001) 0.92
Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol (1999) 0.90
Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. J Virol (1994) 0.89
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology (2008) 0.89
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol (2010) 0.89
A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J Gastroenterol (2004) 0.89
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem (2011) 0.88
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol (2014) 0.87
Public versus personal serotypes of a viral quasispecies. Proc Natl Acad Sci U S A (2003) 0.86
Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. J Virol (2016) 0.85
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunol (2010) 0.84
Update on chronic viral hepatitis. Postgrad Med J (2001) 0.83
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Hepatitis C virus: molecular biology and genetic variability. Dig Dis Sci (1996) 0.81
A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J (2007) 0.81
Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J Gastroenterol (2007) 0.81
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses (2009) 0.80
Separation of Hepatitis C genotype 4a into IgG-depleted and IgG-enriched fractions reveals a unique quasispecies profile. Virol J (2008) 0.79
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines (2016) 0.77
Monitoring of hepatitis C virus quasispecies in chronic infection by matrix-assisted laser desorption ionization-time of flight mass spectrometry mutation detection. J Clin Microbiol (2007) 0.77
Isolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization. PLoS One (2013) 0.76
Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy. Ann Saudi Med (2010) 0.76
Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo. Antimicrob Agents Chemother (2017) 0.75
Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice. World J Gastroenterol (2012) 0.75
Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog (2017) 0.75
Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine. Adv Biomed Res (2015) 0.75
Antigenic structure of the hepatitis C virus envelope 2 protein. Clin Exp Immunol (1994) 0.75
Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol (2016) 0.75
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 4.47
Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 4.47
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A (1992) 3.72
Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci U S A (1992) 3.55
Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun (1991) 3.09
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol (1993) 2.74
A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology (1993) 1.90
Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci U S A (1993) 1.78
Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. Biochem Biophys Res Commun (1992) 1.57
Thermostability of human immunodeficiency virus (HIV-1) in a liquid matrix is far higher than that of an ecotropic murine leukemia virus. Jpn J Cancer Res (1989) 1.17
Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in posttransfusion hepatitis patients during long-term follow-up. J Med Virol (1993) 0.98
Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med (1984) 0.98
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
DNA polymerase associated with human hepatitis B antigen. J Virol (1973) 10.71
Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A (1990) 9.98
Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A (1990) 8.92
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
A colour test for the measurement of antibody to certain mycoplasma species based upon the inhibition of acid production. J Hyg (Lond) (1966) 6.23
Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A (1997) 6.09
A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U S A (1997) 6.07
Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med (1966) 5.97
Color test for the measurement of antibody to T-strain mycoplasmas. J Bacteriol (1966) 5.61
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species. Proc Natl Acad Sci U S A (2001) 4.62
Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol (1987) 4.49
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology (1990) 4.43
Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis (1980) 4.28
Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med (1991) 4.24
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology (1999) 4.04
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol (2002) 3.83
Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. J Virol (1998) 3.73
Mammalian karyopherin alpha 1 beta and alpha 2 beta heterodimers: alpha 1 or alpha 2 subunit binds nuclear localization signal and beta subunit interacts with peptide repeat-containing nucleoporins. Proc Natl Acad Sci U S A (1995) 3.73
Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A (1992) 3.72
Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1989) 3.67
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci U S A (1992) 3.55
A microtiter solid-phase radioimmunoassay for hepatitis A antigen and antibody. J Immunol (1976) 3.53
At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A (1993) 3.37
Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med (1975) 3.31
Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet (1980) 3.31
Australia antigen: large-scale purification from human serum and biochemical studies of its proteins. J Virol (1971) 3.28
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect Immun (1981) 3.18
ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J Infect Dis (1993) 3.06
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature (1983) 3.02
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J Immunol (1971) 2.98
Microtiter solid-phase radioimmunoassay for hepatitis B antigen. Appl Microbiol (1973) 2.96
Molecular cloning and characterization of hepatitis A virus cDNA. Proc Natl Acad Sci U S A (1983) 2.92
Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun (1994) 2.89
Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. Proc Natl Acad Sci U S A (1984) 2.87
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol (1993) 2.84
Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol (1987) 2.83
Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A (1994) 2.83
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
A color test for the measurement of antibody to the non-acid-forming human Mycoplasma species. Am J Epidemiol (1966) 2.81
Transmissible agent in non-A, non-B hepatitis. Lancet (1978) 2.78
Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science (1979) 2.78
Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology (1998) 2.76
Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol (1995) 2.76
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol (1993) 2.74
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 2.73
Structural analysis of cDNA for rat peroxisomal 3-ketoacyl-CoA thiolase. J Biol Chem (1987) 2.72
Amino-terminal presequence of the precursor of peroxisomal 3-ketoacyl-CoA thiolase is a cleavable signal peptide for peroxisomal targeting. Biochem Biophys Res Commun (1991) 2.71
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Compact organization of the hepatitis B virus genome. Hepatology (1989) 2.70
Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis (1987) 2.68
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
Enzyme-linked immunosorbent assay for detection of hepatitis A antigen in stool and antibody to hepatitis A antigen in sera: comparison with solid-phase radioimmunoassay, immune electron microscopy, and immune adherence hemagglutination assay. J Clin Microbiol (1978) 2.64
Characterization of a prototype strain of hepatitis E virus. Proc Natl Acad Sci U S A (1992) 2.64
What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? Lancet (1989) 2.63
Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis (1995) 2.63
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
A complement-fixation test for measuring Australia antigen and antibody. J Infect Dis (1969) 2.58
In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci U S A (1999) 2.56
Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res (1992) 2.56
Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A (1987) 2.56
Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med (1994) 2.55
Complete nucleotide sequence of cDNA and predicted amino acid sequence of rat acyl-CoA oxidase. J Biol Chem (1987) 2.51